Skip to content
Evigrade
CriticalClass Ia antiarrhythmic with antimuscarinic activity×First-generation antipsychotic, diphenylbutylpiperidine derivative

Updated · Methodology

Mechanism

Pimozide prolongs the QT interval, and ventricular arrhythmias, torsade de pointes and sudden death have been reported with it, including at usual doses (pimozide summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, and pimozide label, US Food and Drug Administration, FDA). Disopyramide is a class Ia antiarrhythmic that prolongs the action potential of heart cells (disopyramide SmPC, AEMPS). Like other drugs of this class, it can prolong the QT interval, worsen arrhythmia and cause torsade de pointes (FDA disopyramide label). The US pimozide label anticipates an additive effect on QT with QT-prolonging antiarrhythmics and names class Ia drugs among those that pimozide should not be given with (FDA pimozide label). The enzyme CYP3A4 metabolises both drugs, and CYP2D6 and CYP1A2 also metabolise pimozide (pimozide and disopyramide SmPCs, AEMPS). The documents do not describe either drug as an inhibitor of these enzymes and give no data on how one drug changes the level of the other. According to the US label, pimozide has anticholinergic side effects, and the Spanish disopyramide SmPC states that anticholinergic drugs can increase the atropine-like effects of disopyramide (FDA pimozide label and disopyramide SmPC, AEMPS). The documents do not say this about the pair itself.

Symptoms

QT prolongation itself causes no symptoms and shows only on an electrocardiogram (ECG). A ventricular arrhythmia causes palpitations, dizziness or fainting and can lead to cardiac arrest. With pimozide, QT prolongation, ventricular arrhythmias and torsade de pointes have been reported very rarely. Ventricular tachycardia and ventricular fibrillation, sometimes fatal, cardiac arrest and sudden death have also been reported (pimozide summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). With disopyramide, QT prolongation may occur, and the arrhythmia may worsen and progress to ventricular tachycardia and ventricular fibrillation (disopyramide label, US Food and Drug Administration, FDA). At toxic disopyramide levels, the ECG shows marked QT prolongation, QRS widening and heart block, with repeated fainting due to torsade de pointes, low blood pressure, shock and cardiac arrest (disopyramide SmPC, AEMPS). The atropine-like effects of disopyramide include urinary retention in prostatic enlargement, raised eye pressure in angle-closure glaucoma and paralytic ileus, especially in older people, with anticholinergic drugs or when disopyramide levels rise (disopyramide SmPC, AEMPS).

Management

The combination is contraindicated. The Spanish pimozide summary of product characteristics (SmPC) contraindicates pimozide with drugs known to prolong the QT interval and lists class Ia antiarrhythmics among them, naming disopyramide (pimozide SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The US pimozide label also contraindicates pimozide with QT-prolonging drugs and states that pimozide should not be given with class Ia and III antiarrhythmics. Disopyramide is a class Ia drug that prolongs the QT interval according to its own documents (pimozide label, US Food and Drug Administration, FDA; disopyramide SmPC, AEMPS, and disopyramide label, FDA). The Spanish disopyramide SmPC is less strict: it contraindicates other antiarrhythmics and drugs that may cause ventricular arrhythmias, especially torsade de pointes, but lists pimozide itself among combinations that are not recommended (disopyramide SmPC, AEMPS). No document states how long to wait between stopping one drug and starting the other. The mean half-life of pimozide is about 55 hours (pimozide SmPC, AEMPS). The half-life of disopyramide is 4.4–8.2 hours in healthy people and about 17 hours in severe renal impairment, and it is also longer in hepatic or heart failure (disopyramide SmPC, AEMPS). Pimozide is contraindicated in low potassium or magnesium and clinically significant bradycardia. Do an electrocardiogram (ECG) before starting pimozide and repeat it periodically, and stop pimozide if the QT or heart-rate-corrected QT (QTc) exceeds 500 ms (pimozide SmPC, AEMPS). During disopyramide treatment, monitor the QT interval and QRS duration and stop disopyramide if they lengthen by more than 25%. Monitor potassium and correct it if needed (disopyramide SmPC, AEMPS). Start disopyramide for life-threatening arrhythmias in hospital (disopyramide SmPC, AEMPS, and label, FDA). Avoid diuretics with pimozide, especially those that lower potassium (pimozide SmPC, AEMPS).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Disopyramide

Other interactions with Pimozide